Safely improving patient survival rates in aggressive solid tumors and their metastases with targeted therapy against novel onco-viral targets
Thelper AS is a Norwegian biotechnology company aiming to develop innovative treatments against incurable cancers. We have identified a virally encoded biomarker that is abundantly expressed in aggressive and metastatic solid tumors, but is virtually absent in healthy tissues. Our discovery enables the development of highly precise ADCs targeting cancer cells and their immunosuppressive tumor microenvironment. By sparing healthy cells (minimizing on-target, off-tumor effects) and leveraging next generation linker technologies (minimizing nonspecific effects), Thelper’s ADC candidates will greatly reduce toxicity for patients.
High tumor specificity and the potential to alleviate tumor immunosuppression differentiate our therapeutic ADC candidates along safety and durability lines. Our innovative therapies are also agnostic to viral strain variants, allowing us to reach the full spectrum of target patients suffering from aggressive, solid cancers.